Hygea vct provides investors with access to a diversified portfolio of emerging and established MedTech companies qualifying for investment by a VCT. The board has a strong track record of investing in this area and has a network of personnel with successful P&L responsibility experience in the MedTech sector, both in the UK and internationally.

A key feature of the Hygea investment approach is to ensure that portfolio companies are developed as solutions companies i.e. compete on the basis of value provided to customers (not price) by providing better patient outcomes at lower total cost. The effect of this approach is that portfolio companies tend to be focused around medical devices, drug delivery systems, diagnostics and technology based support services - standalone molecule development companies do not generally qualify as solutions companies.

Further to the prospectus launched by Hygea vct plc on 9th May 2018 regarding an offer of "B" ordinary shares (New "B" Shares) to raise, in aggregate, up to £10 million with an over-allotment facility of up to a further £10 million, the following occurred on 23rd August 2018:

- following receipt of valid applications in excess of the minimum subscription threshold, 3,081,892 New "B" Shares were issued and allotted.

- the investment management agreement with Seneca Partners Limited came into effect.

- the company’s name was resolved to be changed from Hygea vct plc to Seneca Growth Capital VCT plc. Athough the company’s name has changed, the existing share certificates in the old company name remain valid and will not be re-issued.

Please click on Seneca Growth Capital [https://senecavct.co.uk] to access the company’s new website. Information relating to the ordinary shares will be maintained on this site pro tem, and the underlying investments of the ordinary share pool will continue to be managed by the Hygea Commercial Advisory Committee (John Hustler, Charles Breese and Richard Roth).